Weight Loss & Metabolic
Cagrilintide
Also known as: Long-acting amylin analog; sold under the retail label GLP-C
An investigational long-acting analog of amylin, a hormone that helps control appetite, studied alone and combined with semaglutide.
Overview
Amylin is a hormone released with insulin after meals that helps signal fullness. Cagrilintide is a lab-made version modified to last about a week in the body, allowing weekly injection.
What the research has looked at
A phase 2 trial found that cagrilintide produced greater weight loss than placebo, and in that trial it compared favorably with liraglutide, an approved GLP-1 drug. The most advanced work combines it with semaglutide in a product called CagriSema, which is in phase 3 development.
Safety and limits
- The most common side effects in trials were gastrointestinal, such as nausea.
- Long-term safety and outcomes data are still being collected.
- Benefits seen with the combination should not be assumed for cagrilintide alone.
- Products sold outside clinical trials are not made under regulatory oversight, so their content and purity are uncertain.
Regulatory context
Cagrilintide is not an approved single-agent medicine. Readers should check current regulatory status, particularly for CagriSema.
Related pages
See also Tirzepatide and Retatrutide.
References & further reading
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
Educational reference only. Not medical advice. This page does not recommend or describe human use, dosing or sourcing.